Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHighmark Delaware Medicare Advantage Preferred Dru…
    Ask Trek AI about this page
    CurrentHighmark DelawarePolicy N/A

    Preferred Products for Medicare Advantage — Preferred and Non‑Preferred Drug Listings (Medicare Advantage)

    Customize your policy alerts

    Sign up for all Highmark Delaware policy alerts

    Know when Highmark Delaware releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists Highmark Delaware's preferred and non-preferred drugs (including HCPCS/J-codes and biosimilars) for Medicare Advantage products and notes that preferred product status is used as a utilization management tool consistent with CMS guidance. Affects providers submitting claims or requesting prior authorization for Medicare Advantage members.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerHighmark Delaware
    PolicyPreferred Products for Medicare Advantage — Preferred and Non‑Preferred Drug Listings
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and document an adequate therapeutic trial and failure or intolerance to preferred products before requesting coverage for a non-preferred drug.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+unique HCPCS/Q‑codes referenced
    6 monthstypical trial length
    Preferred/Non‑Preferredformulary status pairs
    multipledrug categories listed

    Coverage Criteria and Formulary Status

    Therapeutic category preferred status (partial)

    Preferred and Non-Preferred listings per therapeutic category (partial document).

    Bone Resorption listings: Document shows a Bone Resorption category with Preferred and Non-Preferred product columns; Non-Preferred entries include J0897 (denosumab) listing Prolia and Xgeva and J3111 (Evenity/romosozumab-aqqg).

    Partial table; preferred column content not shown in this chunk

    CIDP and CRSwNP preferred status

    Category-level preferred vs non-preferred designations (partial).

    CIDP listings: CIDP section is shown with Preferred and Non-Preferred designations; Non-Preferred entries include systemic corticosteroids, J9334, Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) and immune globulin therapy.

    Partial fragmentary table

    CRSwNP listings: CRSwNP section shows Preferred and Non-Preferred products; Non-Preferred includes J2182, Nucala (mepolizumab, J2356), Tezspire (tezepelumab-ekko, J2357), Xolair (omalizumab) and Dupixent (dupilumab, NOC).

    Partial content

    Biosimilars and neuromuscular disease products

    Eculizumab biosimilars and generalized myasthenia gravis listings (partial).

    Eculizumab biosimilars group lists HCPCS codes and trade names with Soliris (J1299) and biosimilars Epysqli (Q5151) and Bkemv (Q5152) shown in the Non-Preferred column in this fragment.

    Partial list

    Generalized Myasthenia Gravis: Neuromuscular disease section lists Preferred and Non-Preferred entries; Non-Preferred entries in the fragment include J9332 (Vyvgart, efgartigmod alfa-fcab) and J1303 (Imaavy, nipocalimab-aahu).

    Partial fragment

    Formulary status groupings

    Formulary coverage is presented as Preferred or Non‑Preferred for product groups and specific HCPCS/Q‑codes

    Formulary mapping: Products and biosimilars are grouped and assigned Preferred or Non‑Preferred status (example fragments show infliximab biosimilars (e.g., Avsola Q5121) listed as Preferred while Remicade (infliximab) is Non‑Preferred; bevacizumab biosimilars such as Mvasi (Q5107) are shown Preferred while Avastin (bevacizumab) is Non‑Preferred; pegfilgrastim and other colony stimulating factor mappings are shown with Preferred vs Non-Preferred designations).

    Document provides mappings by product and HCPCS/Q-code; chart is partial

    Approval criteria for non-preferred products

    Non-preferred products may be approved when ALL of the following are met:

    Approval conditions for non-preferred products: 1) Individual has had an adequate therapeutic trial of preferred product(s); 2) There is documented drug therapy failure or documented intolerance to the preferred product(s); 3) Trial and failure/intolerance documentation corresponds to FDA- or compendia-based therapeutic dosing and meets the class-specific trial duration noted in the chart.adequate therapeutic trial typically = 6 months; may vary by therapeutic class

    New therapy = no prior utilization in 365 days.

    None explicitly stated in the provided portions of this document beyond the listing of products as Preferred or Non‑Preferred. The policy text references CMS guidance supporting the use of preferred products as a utilization management tool and indicates that coverage for preferred products applies to FDA‑labeled indications when medically necessary, but it does not include standalone exclusion language in the chunks reviewed here.

    Certain originator biologic products are presented in the table as Non‑Preferred while their biosimilars are shown as Preferred. For example, infliximab originator (Remicade) is listed as Non‑Preferred while infliximab biosimilars such as Avsola (Q5121) and Inflectra (Q5103) are shown as Preferred, which implies formulary substitution preference for biosimilars when clinically appropriate and subject to the policy’s therapeutic‑trial requirements for non‑preferred products.

    The chart provides product‑to‑product preferred/non‑preferred mappings. Examples include: Mvasi (Q5107) listed as Preferred while Avastin (bevacizumab/J9035) is shown as Non‑Preferred; pegfilgrastim biosimilars and originators are grouped with Preferred designations for Neulasta (J2506) and Non‑Preferred listings for specific biosimilars; and trastuzumab mappings (multiple Q/J codes) indicate which trastuzumab products are Preferred versus Non‑Preferred. These pairings in the table determine which HCPCS/J/Q code the plan prefers for coverage and utilization management.

    The document excerpts do not include explicit statements using the phrase "Not Medically Necessary". Instead, coverage status is expressed as Preferred or Non‑Preferred in the product tables, and the requirement for medical necessity is referenced in connection with FDA‑labeled indications and CMS guidance.

    Throughout the table and supporting text the plan indicates products as either Preferred or Non‑Preferred. The policy relies on that designation (rather than an explicit Not Medically Necessary label) to guide utilization management, with approval for non‑preferred agents dependent on meeting the stated trial and documentation requirements.

    Use of a Non‑Preferred product without documentation of an adequate therapeutic trial and documented failure or intolerance to Preferred product(s) may be denied. The policy requires evidence of an adequate therapeutic trial (typically 6 months, but class‑specific trial durations are noted in the chart) and documentation of drug therapy failure or intolerance before a non‑preferred product will be approved.

    HCPCS / J‑code / Q‑code Mappings

    Bone Resorption - Non-Preferred (as presented)HCPCS
    J0897Oral/IV Bisphosphonates / Prolia (denosumab) / Xgeva (denosumab) listed in Non-Preferred row
    J3111Evenity (romosozumab-aqqg) listed
    CIDP / related productsHCPCS
    J9334Systemic corticosteroids / Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) listed
    J2182Immune globulin therapy (CIDP section shows J2182 in CRSwNP preferred column)
    Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) codesHCPCS
    J2182Listed under Preferred for CRSwNP
    J2356Nucala (mepolizumab)
    J2357Tezspire (tezepelumab-ekko)
    J3111Xolair (omalizumab) - appears with J3111 in Non-Preferred
    NOCDupixent (dupilumab) shown with NOC
    Eculizumab BiosimilarsHCPCS
    J1299Soliris (eculizumab)
    Q5151Epysqli (eculizumab-aagh)
    Q5152Bkemv (eculizumab-aeeb)
    Generalized Myasthenia GravisHCPCS
    J9332Vyvgart (efgartigmod alfa-fcab)
    J1303Imaavy (nipocalimab-aahu)
    Additional non-preferred / miscellaneous HCPCS codes mentionedHCPCS
    J9333Appears in non-preferred long list (context unclear in partial document)
    J1602Listed in extended non-preferred text (context unclear)
    J7323Hyaluronan injection code mentioned
    J7318Hyaluronate injection code mentioned
    J7321Hyaluronate related code
    J7328Hyaluronate related code
    J7320Listed among hyaluronan codes
    J7326Listed among hyaluronan codes
    J7327Listed among hyaluronan codes
    J7324Listed among hyaluronan codes
    1–10 of 17
    1/2
    Viscoelastic / hyaluronic acid and related codesHCPCS
    J7321listed in hyaluronic acid / viscoelastic product group
    J7328listed in hyaluronic acid / viscoelastic product group
    J9333listed near hyaluronidase and other products
    Q5151associated with hyaluronic acid entries
    Bevacizumab / anti‑VEGF product codesHCPCS
    J9035Avastin (bevacizumab) and related mappings
    C9257code mapped to aflibercept and other agents in list
    Q5107Mvasi (bevacizumab-awwb) mapping
    Infliximab products and biosimilarsHCPCS
    Q5121Avsola (infliximab-axxq) and related infliximab biosimilar mappings
    J1745Infliximab (billing code referenced with biosimilars)
    Q5103Inflectra (infliximab-dyyb) mapping
    Omalizumab productsHCPCS
    J2357Xolair (omalizumab) referenced as preferred mapping
    Q5154Omalizumab biosimilars group/code referenced
    Oncology biologics (bev, rituximab, trastuzumab)HCPCS
    Q5118Zirabev (bevacizumab-bvzr) mapping
    Q5115Truxima (rituximab-abbs) mapping
    J9312rituximab code reference
    Q5117Kanjinti (trastuzumab-anns) mapping
    J9355trastuzumab code reference
    Pegfilgrastim and colony stimulating factorsHCPCS
    J2506Neulasta (pegfilgrastim) reference
    Q5108Fulphila (pegfilgrastim-jmdb) mapping
    J9361eflapegrastim (Rolvedon) reference
    Mixed covered HCPCS/J and Q codes shown in document fragmentsmixed
    J9356trastuzumab-qyyp
    Q5113hyaluronidase-oysk (listed)
    Q5112listed Q-code (documented in chart)
    Q5116listed Q-code (documented in chart)
    J2506pegfilgrastim (Neulasta and biosimilars)
    Q5108Fulphila (pegfilgrastim-jmdb)
    Q5111Neulasta Onpro (pegfilgrastim) Q-code listing
    J1449listed J-code in pegfilgrastim group
    J9361Rolvedon (eflapegrastim-xnst)
    Q5101Zarxio (filgrastim-sndz)
    1–10 of 22
    1/3
    Adequate therapeutic trial — typical durations
    Typical durationSix months from first dose at FDA- or compendia-based therapeutic doses (typical definition)
    Class variationTrial period may vary by therapeutic class; specific shorter durations (e.g., 3–4 months) are noted in the chart
    Measurement startCounted from first dose of therapy
    Documentation requiredMust document drug therapy failure or intolerance to preferred products during/after the trial

    Prior Authorization, Billing, and Documentation Requirements

    Prior Authorization

    Prior authorization requirement

    Certain drugs listed (including J- and Q-codes) may require prior authorization to ensure safe and effective use consistent with Medicare rules and CMS guidance; providers must obtain PA where indicated prior to administration or billing.

    Prior Authorization

    PA tied to Preferred / Non‑Preferred status

    Prior authorization requirements are applied in the context of formulary status: oncology and biologic agents are designated Preferred or Non‑Preferred by HCPCS/Q‑code and may require PA according to their formulary designation and plan rules.

    Prior Authorization

    PA requirement for non‑preferred products

    Requests for non‑preferred products require prior authorization with documentation showing an adequate therapeutic trial and documented failure or intolerance to preferred products before approval.

    Key Definitions and Terms

    Preferred products
    DefinitionDrugs designated by the plan as preferred for utilization management and cost‑control purposes
    ScopeApplies to professional providers and facility claims for all Highmark Medicare markets
    Coverage applicabilityCoverage for preferred products is applicable to FDA‑labeled indications when determined medically necessary per CMS guidance
    J9035 — bevacizumab mapping
    Code mappingJ9035 is mapped to bevacizumab (Avastin) and related bevacizumab product groupings
    ExamplesDocument lists Avastin (bevacizumab) and biosimilars such as Mvasi (Q5107) and Zirabev (Q5118) within the bevacizumab group

    Initial Coverage Conditions

    Initial therapy requirement

    Initial coverage condition for non-preferred agents

    Initial approval for non-preferred agents: Patient must have had an adequate therapeutic trial of preferred products with documented failure or intolerance; adequate trial is typically six months from first dose at FDA- or compendia-based therapeutic doses but may vary by therapeutic class as noted in the chart. New therapy is defined as no prior utilization within the past 365 calendar days.6 months typical

    Chart contains class-specific deviations (e.g., some entries note 3–4 months).

    Step Therapy and Substitution Rules

    Product group / examplePreferredNon‑PreferredImplication
    Bevacizumab product group
    Mvasi (Q5107); Zirabev (Q5118) listed as preferred biosimilars in chart
    Avastin (bevacizumab) (J9035) listed as Non‑Preferred
    Grouping indicates step/substitution to preferred biosimilar (e.g., Mvasi) is expected before coverage of originator Avastin
    Product group / exampleRequired trial of preferred productsFailure/intolerance documentationApproval condition for non‑preferred
    Infliximab product group
    Adequate therapeutic trial of preferred infliximab biosimilars (e.g., Avsola Q5121, Inflectra Q5103) is required
    Documented drug therapy failure or intolerance to the preferred biosimilars must be provided
    Non‑Preferred Remicade (infliximab) may be approved only after trial and documented failure/intolerance to preferred biosimilars

    Place of Service Applicability

    Billing Rule

    Preferred designations apply to professional and facility claims

    Preferred product designations in this policy apply to professional providers and facility claims across all Highmark Medicare markets, including office, infusion center, hospital outpatient, and professional settings.

    Biosimilar Groupings and Notes

    Billing Rule

    Soliris (eculizumab) listed in eculizumab grouping

    Soliris (eculizumab) and its related biosimilar codes are listed in the eculizumab grouping with preferred vs non‑preferred designations shown in the chart.

    Billing Rule

    Preserve Soliris code mappings in submissions

    Table mappings include duplicate entries for Soliris (eculizumab) and associated biosimilars; preserve the chart mapping when submitting claims or PA requests.

    Billing Rule

    Mvasi preferred; Avastin non‑preferred in bevacizumab group

    Mvasi (Q5107) is listed as Preferred while Avastin (bevacizumab, J9035) is listed as Non‑Preferred within the bevacizumab product grouping—use the preferred biosimilar code when applicable.

    Policy Summary
    PayerHighmark Delaware
    PolicyPreferred Products for Medicare Advantage — Preferred and Non‑Preferred Drug Listings
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and document an adequate therapeutic trial and failure or intolerance to preferred products before requesting coverage for a non-preferred drug.
    SourceLink
    On This Page
    Coverage Criteria and Formulary StatusHCPCS / J‑code / Q‑code MappingsPrior Authorization, Billing, and Documentation RequirementsKey Definitions and TermsInitial Coverage ConditionsStep Therapy and Substitution RulesPlace of Service ApplicabilityBiosimilar Groupings and Notes
    New therapy lookback
    DefinitionNo previous utilization within the last 365 calendar days
    Use in prior‑authUsed to define 'new therapy' for prior authorization and step‑therapy decisions
    Lookback period type365 calendar days (one year)
    • Adequate therapeutic trial typically = six months from first dose at FDA- or compendia-based therapeutic doses (may vary by class).
    • New therapy = no utilization within the last 365 calendar days.
    Note

    Coverage / PA applicability

    Coverage for preferred products applies to FDA‑labeled indications when medically necessary; certain drugs listed in the document may require prior authorization consistent with CMS NCDs, LCDs, and LCAs.

    Step Therapy

    Formulary grouping implies substitution/step

    The formulary groups originator biologics with their biosimilars (e.g., bevacizumab and infliximab groupings), implying that plan-preferred biosimilars are the step or substitution of choice and originator products may be non‑preferred.

    • Example: Mvasi (Q5107) listed as Preferred while Avastin (bevacizumab) is listed Non‑Preferred.
    • Example: Avsola (Q5121) and Inflectra (Q5103) presented as Preferred; Remicade (infliximab) shown Non‑Preferred.
    Step Therapy

    Step therapy / therapeutic trial required

    A therapeutic trial of preferred agent(s) is required before approval of a non‑preferred agent; the trial duration is typically six months but may vary by therapeutic class as noted in the chart.

    • Documented drug therapy failure or intolerance to preferred products is required for approval of the non‑preferred agent.
    Note

    Coverage applies to FDA‑labeled indications; PA may still be required

    Coverage is applicable to FDA‑labeled indications when medically necessary; for certain drugs the plan may still require prior authorization as noted in the policy.

    Billing Rule

    Submit matching HCPCS / J‑code

    Submit the exact HCPCS/J‑code that matches the dispensed product on requests and claims; the document maps specific codes to products and expects matching code submission.

    • Billing the code that corresponds to the administered product (originator vs biosimilar) is required.
    Documentation Required

    Documentation: show adequate trial and failure/intolerance

    Required documentation for PA of non‑preferred products must demonstrate an adequate therapeutic trial and documented drug therapy failure or intolerance to preferred products, with trial duration per chart (typically six months).

    • Document therapy start dates, doses consistent with FDA or compendia recommendations, and objective evidence of failure or intolerance.
    Denial Risk

    UM actions may apply for non‑preferred products

    Use of non‑preferred products or drugs that require prior authorization may result in utilization management actions consistent with CMS guidance; providers should follow PA and documentation requirements to avoid such actions.

    Billing Rule

    Billing non‑preferred codes may trigger denial

    Billing non‑preferred product codes when a preferred biosimilar or alternative is designated may trigger claim denial; submit PA and required documentation if billing a non‑preferred code.

    Denial Risk

    Denial risk if adequate trial not documented

    Requests for non‑preferred drugs can be denied unless the member has had an adequate therapeutic trial with documented drug therapy failure or intolerance to the preferred products.

    • Adequate therapeutic trial is typically six months from first dose at FDA- or compendia-based therapeutic dosing; class-specific durations are noted in the chart.
    Note

    CMS guidance underpins preferred‑product policy

    CMS guidance is the basis for recognizing preferred products as a utilization management tool; follow CMS NCD/LCD/LCA rules when implementing PA and step requirements.

    Use caseMapping supports correct HCPCS/J‑code submission and formulary designation (Preferred vs Non‑Preferred)
    J2506 / Q5108 — pegfilgrastim mappings
    CodesJ2506 and Q5108 are mapped to pegfilgrastim products (Neulasta and biosimilars)
    ExamplesDocument references Neulasta (J2506), Fulphila (Q5108) and multiple pegfilgrastim biosimilars in the group
    Related codesChart also lists Neulasta Onpro, Q5111 and other pegfilgrastim Q‑codes in the pegfilgrastim group
    Adequate therapeutic trial — policy definition
    Primary definitionAdequate therapeutic trial is typically six months from first dose at FDA‑ or compendia‑based therapeutic doses of preferred product
    Class exceptionsTrial duration may vary by therapeutic class; the chart notes some shorter durations (e.g., 3–4 months)
    Approval requirementNon‑preferred requests require documentation of an adequate therapeutic trial and documented failure or intolerance to preferred products
    New therapy — policy definition
    DefinitionNew therapy = no previous utilization within the last 365 calendar days
    ApplicationUsed to determine whether prior trials or step‑therapy requirements apply for non‑preferred product requests
    Lookback window365 calendar days counted prior to the request
    Billing Rule

    Infliximab biosimilars preferred; Remicade non‑preferred

    Infliximab biosimilars (e.g., Avsola Q5121, Inflectra Q5103) are presented as Preferred while the originator Remicade (infliximab) is shown as Non‑Preferred; document prior trials of preferred biosimilars if requesting the originator.

    Billing Rule

    Originator products non‑preferred unless trial/failure of preferred shown

    For groups such as pegfilgrastim, filgrastim, trastuzumab and denosumab, the chart assigns preferred vs non‑preferred status per product; non‑preferred originator products require an adequate trial and documented failure/intolerance of the preferred product(s) for approval.